• Targeted SPP1 Inhibition in Tumor Myeloid Cells

  2026-10-09

  The reference study combines a phenotype-based macrophage screen with a TAM-avid nanodelivery strategy to suppress SPP1 in tumor-associated myeloid cells. Its findings support SPP1-high TAMs as a tractable preclinical target, while the murine evidence remains distinct from clinical validation or proof that the approach will translate across human cancers.

• V5 Epitope Tag Peptide: Evidence and Limits

  2026-10-09

  The V5 Epitope Tag Peptide contains the GKPIPNPLLGLDST peptide sequence used as an antibody-recognized epitope in recombinant protein research. Product specifications support identity and analytical purity, while peer-reviewed evidence supports the broader study of anti-V5 antibody binding and dissociation rather than performance of this specific commercial peptide in every assay.

• KNUCKLES and Hormonal Control of Floral Meristem Termination

  2026-10-08

  A 2025 Plant Cell study identifies KNUCKLES as a transcriptional and chromatin-level coordinator of auxin distribution and cytokinin activity during Arabidopsis floral meristem termination. Its findings extend the established KNU–WUS/CLV3 framework by linking developmental timing to repression of PIN1 and IPT7 through H3K27me3-associated regulation.

• Bortezomib (PS-341) Product Overview

  2026-10-08

  Bortezomib (PS-341), SKU A2614, is described by APExBIO as a reversible 20S proteasome inhibitor for research involving proteasome-regulated cellular processes and apoptosis signaling. No matched paper evidence was provided, so product claims are not independently assessed here.

• Mecamylamine Hydrochloride: Receptor-Level Context

  2026-10-07

  Mecamylamine hydrochloride offers a valuable receptor-level lens for interpreting gut–brain cholinergic signaling. This article distinguishes what mecamylamine can reveal about nicotinic transmission from what the latest Bacteroides fragilis epilepsy study does—and does not—demonstrate.

• Digoxin: Cardiac and Antiviral Research Context

  2026-10-07

  Digoxin is a cardiac glycoside and Na+/K+ ATPase pump inhibitor with an established cardiovascular role and a more preliminary research profile in chikungunya virus studies. Clinical evidence supports symptom and hospitalization-related benefits in selected heart-failure contexts, while antiviral findings remain cell-based, incompletely sourced, and unsuitable for direct clinical extrapolation. This overview compares the evidence, clarifies provenance, and identifies key limitations.

• CSBTA Pharmacokinetics in MASH Models

  2026-10-06

  The 2025 study in Biomedicine & Pharmacotherapy integrates pharmacokinetic profiling, tissue distribution, transporter assays, microsomal metabolism, and regulatory analysis to explain how an HFHCD-induced disease state changes exposure to three Corydalis saxicola Bunting total alkaloids. Its main implication is that disease-associated changes in CYP450 enzymes, Oatp1b2, P-gp, and PXR-related regulation may contribute to pharmacokinetic variability during repeated treatment, although translation from mice to patients remains uncertain.

• USP36, Snail1, and Ribotoxic Stress in Cancer

  2026-10-06

  The reference study identifies a JNK–HSF1–USP36–Snail1 pathway that helps solid-tumor cells preserve ribosome biogenesis and survive ribotoxic stress. Its central implication is that ribosome-directed therapy may be improved by blocking an adaptive nucleolar survival response rather than targeting translation inhibition alone.

• BCECF-AM and Plant Autophagy pH Research

  2026-10-05

  BCECF-AM is a ratiometric fluorescent pH indicator used to study intracellular acid–base changes. This overview places the probe in the context of a 2026 Arabidopsis study linking SINAT proteins, VAB1, V-ATPase activity, vacuolar acidification and autophagic vesicle degradation, while separating established findings from possible applications and important evidence limitations.

• Vemurafenib and Melanoma Resistance: Evidence Overview

  2026-10-05

  Vemurafenib, also known as PLX4032, is a BRAF-targeted research compound used to study MAPK signaling and drug resistance in BRAF-mutant melanoma models. This overview compares supplier-described pharmacology with a recent multi-omics study of ARID1A-associated resistance, emphasizing evidence strength, model limitations, and the boundaries between mechanistic findings and therapeutic interpretation.

• FITC-Concanavalin A Conjugate Overview

  2026-10-04

  FITC-Concanavalin A (ConA) Conjugate is a fluorescein-labeled lectin product described for conceptual detection of α-D-glucose- and α-D-mannose-containing glycans. No matched paper evidence was provided, so performance and application claims remain unvalidated here.

• JZL184: MAGL Inhibitor and Endocannabinoid Signaling

  2026-10-03

  JZL184 is a selective monoacylglycerol lipase inhibitor that reduces 2-arachidonoylglycerol hydrolysis and increases endocannabinoid tone in preclinical models. Evidence supports its use for studying CB1 receptor mediated synaptic modulation, analgesia and antinociception research, and cannabinoid-related behavioral adaptation, but not as a direct clinical treatment.

• EPZ-6438 Workflow for EZH2-Dependent Cancer Models

  2026-10-02

  EPZ-6438 is a selective EZH2 inhibitor for connecting PRC2 activity with H3K27me3 loss, transcriptional remodeling, cell-cycle arrest, and apoptosis. This practical guide adapts the compound to HPV-associated cervical cancer, malignant rhabdoid tumor, and EZH2-mutant lymphoma workflows while emphasizing formulation, controls, and interpretation limits.

• Nocodazole: A Reversible Lens on Mitosis

  2026-10-01

  Nocodazole is more than a mitotic arrest reagent. As a reversible microtubule polymerization inhibitor, it can connect spindle mechanics with cell-cycle signaling, translation control, trafficking, and anticancer drug evaluation—provided researchers separate direct tubulin effects from context-dependent kinase and stress responses.

• HyperScribe™ mRNA Kit: From T7 to Delivery

  2026-10-01

  The HyperScribe™ mRNA synthesis kit integrates T7 transcription, ARCA capping, 5-moUTP incorporation, and poly(A) tailing in one workflow. This guide connects reaction design with downstream RNA-delivery decisions, using recent PVX nanotechnology research to explain how transcript quality shapes practical assay interpretation.

8173 records 2/545 page Previous Next 12345 下5页 Last page